Amgen's decision to block reinstatement of GDNF is faulted by a leading Parkinson's advocacy group

effects of Parkinson's disease. Since the trial was halted last summer, many of these people, supported by organizations and thousands of well-wishers from around the Parkinson's community, have pleaded with Amgen to reinstate those subjects who wish to continue with the treatment and are willing to be carefully followed to generate ongoing data. We understand and fully accept that such reinstatement of treatment should take place only with appropriate waivers that would hold the company harmless in event of any complications, whether foreseen or unforeseen, and with the approval of the relevant Institutional Review Boards."

"The safety issues of neutralizing antibodies (found in some of the human subjects) and of cerebellar degeneration involving high-dosage GDNF (in some non-human primate subjects) need to be investigated and understood. If subjects are willing to offer themselves for continuing GDNF infusion with all of these safety concerns fully explained and understood by the subjects, then the Parkinson community science as well as patients can gain much new information related to the safety of GDNF infusions."

"In summary, the decision is a mistake because it denies the patients and their doctors the opportunity to continue with a potentially useful, albeit yet unproven, treatment, and it denies us all the opportunity to gather more scientific data about the long-term effects of GDNF. We hope very much that this company, which has long held a position of high respect in the business and health communities, will consider reversing its decision, and soon. In the meantime, the coalition of patient-voluntary groups which besides PDF includes the Parkinson's Action Network and the Parkinson's Pipeline Project -- will continue fighting for patients' interests as long as it takes."


Contact: Christiana Evers
Parkinson's Disease Foundation

Page: 1 2

Related biology news :

1. A nurse makes the decision on who will live
2. Cells use noise to make cell-fate decisions
3. Group decisions: From compromise to leadership in pigeon homing
4. AIUM supports FDA decision to deny over-the-counter use of handheld doppler fetoscopes
5. Titans of biodiversity science call for united, authoritative voice to inform decision-makers
6. Dover intelligent design decision to be topic of national forum
7. Honeybee decision-making ability rivals any department committee
8. Even at small scales, the big decisions are made at the water cooler
9. Amid growing public concerns, bioscience firms begin formalizing ethical decision-making practices
10. Ethical decision-making at bioscience companies
11. Dover decision is good for long-term economic and scientific strength

Post Your Comments:

(Date:10/8/2015)... , Oct. 8, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, announced today that it will report ... 2016 on Thursday, October 22, 2015, after the ... corresponding conference call for analysts and investors at ... management may discuss forward-looking information.    ...
(Date:10/7/2015)... October 7, 2015 NXTD ) ... on the growing mobile commerce market and creator of ... Washington , former long- term executive at American Express ... --> NXTD ) ("NXT-ID" or the "Company"), a ... market and creator of the Wocket® smart wallet announces ...
(Date:10/2/2015)... , Oct. 02 2015 ... of the "Enforcing the Law Using Biometrics" ... http://www.researchandmarkets.com/research/6kp5mx/enforcing_the_law ) has announced the addition of the ... to their offering. --> Research and ... of the "Enforcing the Law Using Biometrics" ...
Breaking Biology News(10 mins):
(Date:10/13/2015)... Research and Markets( http://www.researchandmarkets.com/research/cz7mz7/us_and_europe ) has announced ... for Bone Morphogenetic Protein Growth Factor Therapy - 16 ... --> --> Bone morphogenetic proteins ... bone after a fracture. In nature, these proteins have ... of the skeleton. There are twenty different BMPs that ...
(Date:10/13/2015)... and SAN DIEGO , Oct. 13, ... Inc. have agreed to collaborate in the development of ... NF, marketed by BASF under the Kolliphor ® ... of pharmaceutical and biological applications, such as a shear ... starting material for Mast,s lead product candidate. Under the ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... distributor of automation systems, material handling solutions and components, is opening its latest ... near State Street, the facility is Exotic’s second major expansion in Metropolitan Detroit ...
(Date:10/13/2015)... , October 13, 2015 the ... Europe .  PRCC represents about 14% of all new ... States , Canada and ... of kidney cancer.   --> Hutchison China MediTech Limited ... drug R&D subsidiary, and AstraZeneca AB (publ) ("AstraZeneca") have completed enrolment ...
Breaking Biology Technology:
Cached News: